{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:27:11Z","timestamp":1786991231684,"version":"build-2736575974"},"reference-count":68,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T00:00:00Z","timestamp":1706745600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013412","name":"Sanofi Espa\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013412","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaci-global.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology: Global"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1016\/j.jacig.2023.100174","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T21:34:58Z","timestamp":1695850498000},"page":"100174","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effect of biologics in lung function and quality of life of patients with united airways disease: A\u00a0systematic review"],"prefix":"10.1016","volume":"3","author":[{"given":"Javier","family":"Dom\u00ednguez-Ortega","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Mullol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Javier","family":"\u00c1lvarez Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celia","family":"Miguel-Blanco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Antonio","family":"Castillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Mar\u00eda","family":"Olaguibel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5012-1746","authenticated-orcid":false,"given":"Marina","family":"Blanco-Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacig.2023.100174_bib1","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jaip.2020.09.063","article-title":"Chronic rhinosinusitis with nasal polyps and asthma","volume":"9","author":"Laidlaw","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib2","first-page":"00484","article-title":"Management of united airway disease focused on patients with asthma and chronic rhinosinusitis with nasal polyps: a systematic review","volume":"S2213-2198","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib3","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/02770903.2021.1879130","article-title":"Manifesto on united airways diseases (UAD): an Interasma (global asthma association - GAA) document","volume":"59","author":"Tiotiu","year":"2022","journal-title":"J Asthma"},{"key":"10.1016\/j.jacig.2023.100174_bib4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2500\/ajra.2016.30.4304","article-title":"Asthma in ear, nose, and throat primary care patients with chronic rhinosinusitis with nasal polyps","volume":"30","author":"Frend\u00f8","year":"2016","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib5","article-title":"Regulation of interaction between the upper and lower airways in united airway disease","volume":"7:27","author":"Kanda","year":"2019","journal-title":"Med Sci (Basel)"},{"key":"10.1016\/j.jacig.2023.100174_bib6","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1111\/all.13496","article-title":"Precision medicine in united airways disease: a \u201ctreatable traits\u201d approach","volume":"73","author":"Yii","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib7","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib8","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2500\/ajra.2011.25.3613","article-title":"Association between severity of asthma and degree of chronic rhinosinusitis","volume":"25","author":"Lin","year":"2011","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/all.13599","article-title":"Diagnosis and management of NSAID-exacerbated respiratory disease (N-ERD)\u2014a EAACI position paper","volume":"74","author":"Kowalski","year":"2019","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib10","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1016\/j.jaip.2022.03.002","article-title":"Chronic rhinosinusitis with nasal polyps: quality of life in the biologics era","volume":"10","author":"Mullol","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib11","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/alr.22064","article-title":"Asthma onset pattern and patient outcomes in a chronic rhinosinusitis population","volume":"8","author":"John Staniorski","year":"2018","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2023.100174_bib12","first-page":"45","article-title":"Nasal polyps in patients with asthma: prevalence, impact, and management challenges","volume":"9","author":"Langdon","year":"2016","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4193\/Rhin20.401","article-title":"European Position Paper on Rhinosinusitis and Nasal Polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2023.100174_bib14","doi-asserted-by":"crossref","first-page":"873","DOI":"10.2147\/JAA.S258438","article-title":"Management of chronic rhinosinusitis with nasal polyposis in the era of biologics","volume":"14","author":"Morse","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib15","unstructured":"GINA. Global Strategy for Asthma Management and Prevention. In: Global Initiative for Asthma; 2022. Available at: https:\/\/ginasthma.org\/wp-content\/uploads\/2022\/05\/GINA-Main-Report-2022-FINAL-22-05-03-WMS.pdf. Accessed October 16, 2023."},{"key":"10.1016\/j.jacig.2023.100174_bib16","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacig.2023.100174_bib17","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2023.100174_bib18","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib19","unstructured":"GEMA 5.2. Gu\u00eda Espa\u00f1ola para el Manejo del Asma. In: Sociedad Espa\u00f1ola de Neumolog\u00eda y Cirug\u00eda Tor\u00e1cica; 2022; www.gemasma.com."},{"key":"10.1016\/j.jacig.2023.100174_bib20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib21","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.jaip.2018.08.021","article-title":"Effects of reslizumab on asthma outcomes in a subgroup of eosinophilic asthma patients with self-reported chronic rhinosinusitis with nasal polyps","volume":"7","author":"Weinstein","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jacig.2023.100174_bib23","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions","volume":"10","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacig.2023.100174_bib24","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jacig.2023.100174_bib25","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1111\/cea.13852","article-title":"Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): a randomized double-blind placebo-controlled trial","volume":"51","author":"Tversky","year":"2021","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib26","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1111\/all.14902","article-title":"Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis","volume":"77","author":"Canonica","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.rmed.2020.106080","article-title":"Efficacy of benralizumab in severe asthma in real life and focus on nasal polyposis","volume":"171","author":"Bagnasco","year":"2020","journal-title":"Respir Med"},{"key":"10.1016\/j.jacig.2023.100174_bib28","doi-asserted-by":"crossref","first-page":"435","DOI":"10.14639\/0392-100X-N0716","article-title":"Effects of biological therapies on chronic rhinosinusitis in severe asthmatic patients","volume":"40","author":"Bandi","year":"2020","journal-title":"Acta Otorhinolaryngol Ital"},{"key":"10.1016\/j.jacig.2023.100174_bib29","doi-asserted-by":"crossref","DOI":"10.1177\/2058738420950851","article-title":"Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma","volume":"34","author":"Lombardo","year":"2020","journal-title":"Int J Immunopathol Pharmacol"},{"key":"10.1016\/j.jacig.2023.100174_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101965","article-title":"Rapid effect of benralizumab for severe asthma with chronic rhinosinusitis with nasal polyps","volume":"64","author":"Matsuno","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jacig.2023.100174_bib31","doi-asserted-by":"crossref","first-page":"785","DOI":"10.4081\/mrm.2021.785","article-title":"Real world effectiveness of benralizumab on respiratory function and asthma control","volume":"16","author":"Menzella","year":"2021","journal-title":"Multidiscip Respir Med"},{"key":"10.1016\/j.jacig.2023.100174_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.pupt.2020.101966","article-title":"Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma","volume":"64","author":"Menzella","year":"2020","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1016\/j.jacig.2023.100174_bib33","doi-asserted-by":"crossref","first-page":"4371","DOI":"10.1016\/j.jaip.2021.08.004","article-title":"Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study","volume":"9","author":"Nolasco","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib34","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-020-01248-x","article-title":"Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study","volume":"20","author":"Numata","year":"2020","journal-title":"BMC Pulm Med"},{"key":"10.1016\/j.jacig.2023.100174_bib35","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item Sinonasal Outcome Test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"10.1016\/j.jacig.2023.100174_bib36","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.jacig.2023.100174_bib37","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/all.13984","article-title":"Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis","volume":"75","author":"Bachert","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib38","doi-asserted-by":"crossref","first-page":"E1770","DOI":"10.1002\/lary.29230","article-title":"The effect of dupilumab on intractable chronic rhinosinusitis with nasal polyps in Japan","volume":"131","author":"Fujieda","year":"2021","journal-title":"Laryngoscope"},{"key":"10.1016\/j.jacig.2023.100174_bib39","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/all.14906","article-title":"Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS-52 is unaffected by eosinophilic status","volume":"77","author":"Fujieda","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib40","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1002\/alr.22780","article-title":"Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"11","author":"Hopkins","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2023.100174_bib41","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/all.15222","article-title":"Dupilumab improves health related quality of life: results from the phase 3 SINUS studies","volume":"77","author":"Lee","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib42","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.jaip.2019.07.016","article-title":"Dupilumab efficacy in uncontrolled, moderate-to-severe asthma with self-reported chronic rhinosinusitis","volume":"8","author":"Maspero","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jacig.2023.100174_bib43","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1111\/all.15067","article-title":"Efficacy and safety of dupilumab in patients with uncontrolled severe CRSwNP and a clinical diagnosis of NSAID-ERD: results from two randomized placebo-controlled phase 3 trials","volume":"77","author":"Mullol","year":"2022","journal-title":"Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib44","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.anai.2021.01.012","article-title":"Dupilumab improves upper and lower airway disease control in chronic rhinosinusitis with nasal polyps and asthma","volume":"126","author":"Laidlaw","year":"2021","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib45","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.jaci.2022.04.007","article-title":"Rapid and sustained effect of dupilumab on clinical and mechanistic outcomes in aspirin-exacerbated respiratory disease","volume":"150","author":"Buchheit","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib46","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000027471","article-title":"Management of chronic rhinosinusitis with nasal polyps in Samter triad by low-dose ASA desensitization or dupilumab","volume":"100","author":"Bertlich","year":"2021","journal-title":"Medicine"},{"key":"10.1016\/j.jacig.2023.100174_bib47","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1002\/alr.22951","article-title":"Outcomes of dupilumab treatment versus endoscopic sinus surgery for chronic rhinosinusitis with nasal polyps","volume":"12","author":"Dharmarajan","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2023.100174_bib48","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.2147\/JAA.S328988","article-title":"Short-term evaluation of dupilumab effects in patients with severe asthma and nasal polyposis","volume":"14","author":"Pelaia","year":"2021","journal-title":"J Asthma Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib49","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib50","doi-asserted-by":"crossref","first-page":"213","DOI":"10.23822\/EurAnnACI.1764-1489.94","article-title":"Favorable clinical efficacy of mepolizumab on the upper and lower airways in severe eosinophilic asthma: a 48-week pilot study","volume":"51","author":"Kurosawa","year":"2019","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib51","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1002\/alr.22774","article-title":"Benefits of biologic therapy administered for asthma on co-existent chronic rhinosinusitis: a real-world study","volume":"11","author":"Bajpai","year":"2021","journal-title":"Int Forum Allergy Rhinol"},{"key":"10.1016\/j.jacig.2023.100174_bib52","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1159\/000507996","article-title":"A comprehensive evaluation of mepolizumab effectiveness in a real-life setting","volume":"181","author":"Cameli","year":"2020","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.waojou.2020.100462","article-title":"Real-life effectiveness of mepolizumab in patients with severe refractory eosinophilic asthma and multiple comorbidities","volume":"13","author":"Crimi","year":"2020","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jacig.2023.100174_bib54","doi-asserted-by":"crossref","DOI":"10.1177\/17534666211009398","article-title":"Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study","volume":"15","author":"Detoraki","year":"2021","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jacig.2023.100174_bib55","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab effectiveness and identification of super-responders in severe asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacig.2023.100174_bib56","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3906\/sag-1912-62","article-title":"Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study","volume":"50","author":"Yilmaz","year":"2020","journal-title":"Turk J Med Sci"},{"key":"10.1016\/j.jacig.2023.100174_bib57","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1164\/rccm.201103-0396OC","article-title":"Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study","volume":"184","author":"Castro","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jacig.2023.100174_bib58","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.jaci.2012.07.047","article-title":"Omalizumab is effective in allergic and nonallergic patients with nasal polyps and asthma","volume":"131","author":"Gevaert","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib59","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jaci.2021.07.045","article-title":"Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study","volume":"149","author":"Gevaert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib60","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1177\/19458924211030486","article-title":"Defining the efficacy of omalizumab in nasal polyposis: a POLYP 1 and POLYP 2 subgroup analysis","volume":"36","author":"Damask","year":"2022","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib61","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13601-020-00330-1","article-title":"Effectiveness of omalizumab in patients with severe allergic asthma with and without chronic rhinosinusitis with\u00a0nasal polyps: a PROXIMA study post hoc analysis","volume":"10","author":"Heffler","year":"2020","journal-title":"Clin Transl Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib62","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1177\/1945892420972326","article-title":"Effects of omalizumab treatment in patients with recalcitrant nasal polyposis and mild asthma: a multicenter retrospective study","volume":"35","author":"Armengot-Carceller","year":"2021","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jacig.2023.100174_bib63","doi-asserted-by":"crossref","first-page":"42","DOI":"10.4193\/Rhin17.139","article-title":"Omalizumab treats chronic rhinosinusitis with nasal polyps and asthma together\u2014a real life study","volume":"56","author":"Bidder","year":"2018","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2023.100174_bib64","doi-asserted-by":"crossref","DOI":"10.4081\/monaldi.2020.1397","article-title":"A multicenter approach to evaluate omalizumab effectiveness in Samter\u2019s triad","volume":"90","author":"Cameli","year":"2020","journal-title":"Monaldi Arch Chest Dis"},{"key":"10.1016\/j.jacig.2023.100174_bib65","first-page":"226","article-title":"Omalizumab in patients with NSAIDs-exacerbated respiratory disease","volume":"58","author":"Forster-Ruhrmann","year":"2020","journal-title":"Rhinology"},{"key":"10.1016\/j.jacig.2023.100174_bib66","doi-asserted-by":"crossref","first-page":"470","DOI":"10.18176\/jiaci.0602","article-title":"Omalizumab as a therapeutic option for nasal polyposis in moderate-to-severe persistent allergic asthma: evidence from a prospective study in a real-world setting","volume":"30","author":"Ruiz-Hornillos","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib67","doi-asserted-by":"crossref","first-page":"49","DOI":"10.18176\/jiaci.0391","article-title":"Effectiveness of omalizumab in severe allergic asthma and nasal polyposis: a real-life study","volume":"30","author":"Tiotiu","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"key":"10.1016\/j.jacig.2023.100174_bib68","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A\u00a0systematic review for the EAACI Guidelines\u2014recommendations on the use of biologicals in severe asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"}],"container-title":["Journal of Allergy and Clinical Immunology: Global"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829323000991?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772829323000991?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T13:12:53Z","timestamp":1757423573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772829323000991"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":68,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["S2772829323000991"],"URL":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100174","relation":{},"ISSN":["2772-8293"],"issn-type":[{"value":"2772-8293","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effect of biologics in lung function and quality of life of patients with united airways disease: A\u00a0systematic review","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology: Global","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacig.2023.100174","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}],"article-number":"100174"}}